Paul Hastings, a leading global law firm, announced today that the firm has once again been recognized as one of the most innovative law firms in Asia-Pacific in the Financial Times Innovative Lawyers Asia-Pacific 2021 report. The firm was also shortlisted in the Practice of Law – Healthcare category for our work advising Shanghai Fosun Pharmaceutical on forming a strategic alliance with BioNTech to develop and commercialize a vaccine that prevents COVID-19 infections using BioNTech’s mRNA vaccine candidate BNT162.

This recognition came on the heels of Paul Hastings winning Firm of the Year – Healthcare & Life Sciences (International) and Deal of the Year – M&A at the China Law & Practice Awards 2020. It also followed the firm’s strong showing in the Financial Times Innovative Lawyers North America 2020 report, in which Paul Hastings ranked among top 10 overall most innovative firms, the top five most digital firms and the top five business and practice leaders, as well as the FT’s Innovative Lawyers Europe 2020 report, in which Paul Hastings was named a highly commended firm in the Responding to Covid-19 and Innovation in the Practice of Law categories, and among the top 10 most innovative practitioners.

The Financial Times’ Innovative Lawyers report is one of the top legal rankings in Asia-Pacific region and highly regarded around the world.

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.